A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : SDAI / Simplified Disease Activity Index

[Related PubMed/MEDLINE]
Total Number of Papers: 242
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   SDAI  (>> Co-occurring Abbreviation)
Long Form:   Simplified Disease Activity Index
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 A Proposal to Standardize Low Disease Activity Criteria in Rheumatoid Arthritis Based on the Outcome Measures in Rheumatology Minimal Disease Activity Definition. CDAI, DAS28, ESR, OMERACT, RA, RAPID3, SJC
2020 Assessment of the association of baseline anti-CarbV and anti-MCV antibodies with response to treatment and radiographic progression in an RA population treated with either methotrexate or baricitinib: post-hoc analyses from RA-BEGIN. anti-CarbV, CFB, Ig, MMRMs, MTX, RA
2020 Baricitinib in patients with rheumatoid arthritis with inadequate response to methotrexate: results from a phase 3 study. ACR20, DAS28, HAQ-DI, JAK, MTX, RA
2020 Baseline Objective Inflammation by Magnetic Resonance Imaging as a Predictor of Therapeutic Benefit in Early Rheumatoid Arthritis With Poor Prognosis. AVERT, CDAI, MRI, MTX, RA
2020 Brief Report: Adaptation of American College of Rheumatology Rheumatoid Arthritis Disease Activity and Functional Status Measures for Telehealth Visits. ACR, CDAI, HAQ-II, MDHAQ, PAS-II, RA, RAPID3
2020 Clinical effectiveness of iguratimod based on real-world data of patients with rheumatoid arthritis. AEs, CDAI, DAS, IGU, MTX, RA
2020 Differences in disease activity measures in patients with rheumatoid arthritis who achieved DAS, SDAI, or CDAI remission but not Boolean remission. CDAI, RA
2020 Effects of biologic drugs on the prognosis of rheumatoid arthritis among patients with poor diabetes control. bDMARDs, DM, PSL, RA
2020 Efficacy and Safety of PF-06651600 (Ritlecitinib), a Novel JAK3/TEC Inhibitor, in Patients With Moderate-to-Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate. AEs, RA, TEC
10  2020 German guidelines for the treatment of rheumatoid arthritis withdisease modifying anti-rheumatic drugs - What is new? b or ts, csDMARD, RA
11  2020 Intake frequency of vegetables or seafoods negatively correlates with disease activity of rheumatoid arthritis. DAS28-ESR, DMARDs, FFQ, HAQ, KURAMA, MMP-3, RA
12  2020 Is CDAI comparable to DAS 28 and SDAI regarding inter-observer agreement and correlation to MHAQ in Egyptian RA patients? CDAI, DAS28, MHAQ
13  2020 Is treat-to-target really working in rheumatoid arthritis? a longitudinal analysis of a cohort of patients treated in daily practice (RA BIODAM). ACR/EULAR, BIODAM, CDAI, RA
14  2020 Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritis. CDAI, DAPSA, MDA, PASDAS, PsA, VLDA
15  2020 Pooled analysis of TNF inhibitor biosimilar studies comparing radiographic progression by disease activity states in rheumatoid arthritis. CDAI, DAS28, HDA, LDA, MDA, mTSS
16  2020 Predictors of long-term clinical remission in rheumatoid arthritis. bDMARD, HRs, MST, MTX, RA
17  2020 Rheumatoid arthritis disease activity and the risk of aseptic arthroplasty loosening. DA, OA, RA, RCL, THA/TKA
18  2020 Simplified disease activity changes in real-world practice: a nationwide observational study of seropositive rheumatoid arthritis patients with moderate-to-high disease activity. DMARD, HAQ, RA
19  2020 Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial. IFX, TNF-alpha
20  2020 Testing different thresholds for patient global assessment in defining remission for rheumatoid arthritis: are the current ACR/EULAR Boolean criteria optimal? ACR/EULAR, CART, PGA, RA
21  2020 The Patient Experienced Symptom State (PESS): a patient-reported global outcome measure that may better reflect disease remission status. CDAI, PESS, RAID
22  2020 Validity and responsiveness of the Work Functioning Impairment Scale (WFun) in rheumatoid arthritis patients: A multicenter prospective study. CDAI, HAQ-DI, RA, WFun, WPAI
23  2019 2-D speckle-tracking assessment of left and right ventricular function in rheumatoid arthritis patients with and without disease activity. DAS28, GLS, LV, RA, ROC, RV, STE
24  2019 Clinical deep remission and related factors in a large cohort of patients with rheumatoid arthritis. CliDR, csDMARDs, DAS28, DAS28-ESR, DMARD, RA, RAPID3
25  2019 Correlation of the Multi-Biomarker Disease Activity Score With Rheumatoid Arthritis Disease Activity Measures: A Systematic Review and Meta-Analysis. CDAI, MBDA, RA, RAPID3
26  2019 Disease activity improvements with optimal discriminatory ability between treatment arms: applicability in early and established rheumatoid arthritis clinical trials. CDAI, RA
27  2019 Effect of disease duration and prior disease-modifying antirheumatic drug use on treatment outcomes in patients with rheumatoid arthritis. ACR, DMARDs, HAQ-DI, RA
28  2019 Iguratimod, a synthetic disease modifying anti-rheumatic drug inhibiting the activation of NF-kappaB and production of RANKL: Its efficacy, radiographic changes, safety and predictors over two years' treatment for Japanese rheumatoid arthritis patients. GSS, IGU, RA
29  2019 Influence of seasonal changes on disease activity and distribution of affected joints in rheumatoid arthritis. CDAI, DAS
30  2019 Normal serum matrix metalloproteinase-3 levels can be used to predict clinical remission and normal physical function in patients with rheumatoid arthritis. CRP, MMP-3, RA
31  2019 Precision medicine using different biological DMARDs based on characteristic phenotypes of peripheral T helper cells in psoriatic arthritis. bDMARDs
32  2019 Prevalence of feet and ankle arthritis and their impact on clinical indices in patients with rheumatoid arthritis: a cross-sectional study. CDAI, DAS28, FAA, MTP, RA, RAPID3
33  2019 Prevalence of sustained remission in rheumatoid arthritis: impact of criteria sets and disease duration, a Nationwide Study in Sweden. CDAI, SR
34  2019 Relapse in rheumatoid arthritis patients undergoing dose reduction and withdrawal of biologics: are predictable factors more relevant than predictive parameters? An observational prospective real-life study. bDMARDs, RA, US
35  2019 Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension. CDAI, LDA, OLE
36  2019 Sustained clinical remission of rheumatoid arthritis and its predictive factors in an unselected adult Chinese population from 2009 to 2018. 6-month SR, CDAI, DAS28-ESR, RA, SR
37  2019 Translating Treatment Effects Between Rheumatoid Arthritis Activity Measures and American College of Rheumatology Responses in Direct Comparison Trials. ACR, ACR20, DAS28, RA
38  2019 Usefulness of composite indices in the assessment of joint involvement in systemic lupus erythematosus patients: correlation with ultrasonographic score. CDAI, DAS28, SLE, STR, US
39  2019 Validity and interpretability of the QuickDASH in the assessment of hand disability in rheumatoid arthritis. HAQ-DI, HDA, LDA, MDA, RA, REM, ROAD
40  2018 Azilsartan improves the effects of etanercept in patients with active rheumatoid arthritis: a pilot study. Azil, CDAI, DAS28, ETAN, HAQ-DI, RA, RAS
41  2018 Changes in thiol/disulfide homeostasis in juvenile idiopathic arthritis. JIA
42  2018 Common Evaluations of Disease Activity in Rheumatoid Arthritis Reach Discordant Classifications across Different Populations. CDAI, DAS28-ESR, RA
43  2018 Comorbidities in rheumatic arthritis. RA
44  2018 Comparison of composite indices with global synovitis score on ultrasound for detecting remission. CDAI, DAS28, GLOESS, RA
45  2018 Defining and characterizing sustained remission in patients with rheumatoid arthritis. RA, SD, SEAM-RA, TNFi
46  2018 Effect of medication adherence on disease activity among Japanese patients with rheumatoid arthritis. DAS28-ESR, DMARDs, HAQ, RA
47  2018 Effect of Treat-to-target Strategies Aiming at Remission of Arterial Stiffness in Early Rheumatoid Arthritis: A Randomized Controlled Study. AIx, PWV, RA
48  2018 Effect of treat-to-target strategies on bone erosion progression in early rheumatoid arthritis: An HR-pQCT study. BMD, ERA, HR-pQCT
49  2018 Is the serum oxytocin level altered by treatment in rheumatoid arthritis patients complicated with depression? ADL, BMI, CRP, ESR, HAM-D, MCS, MMP-3, OXT, QOL, RA, SF
50  2018 Oral Methotrexate in split dose weekly versus oral or parenteral Methotrexate once weekly in Rheumatoid Arthritis: a short-term study. ACR, LDA, MTX, RA
51  2018 Origins of Discordant Responses among 3 Rheumatoid Arthritis Improvement Criteria. ACR, ACR20, EULAR, RA
52  2018 Performance of routine assessment of patient index data 3 (RAPID3) in monitoring disease activity of Chinese rheumatoid arthritis patients. CDAI, CRP, DAS28, ESR, RA, RAPID3
53  2018 Performances of Clinical Disease Activity Index (CDAI) andSimplified Disease Activity Index (SDAI) appear to be better than the gold standard Disease Assessment Score (DAS-28-CRP) to assess rheumatoid arthritis patients. CDAI, DAS-28-CRP, RA
54  2018 Predicting achievement of the treatment targets at 6 months from 3-month response levels in rheumatoid arthritis: data from real-life follow-up in the NOR-DMARD study. RA
55  2018 Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active rheumatoid arthritis: results of the PRESERVE trial. BMI, CDAI, DAS28, HAQ, PROs, RA
56  2018 Predictors of sustained remission in patients with early rheumatoid arthritis treated according to an aggressive treat-to-target protocol. OR
57  2018 Real World Experience of Disease Activity in Patients With Rheumatoid Arthritis and Response to Treatment With Varios Biologic DMARDs. ADA, bDMARDs, CDAI, CRP, csDMARD, ETN, GOL, RA, RTX, TCL
58  2018 Relevance of P-glycoprotein on CXCR4+ B cells to organ manifestation in highly active rheumatoid arthritis. IDL, P-gp, RA
59  2018 Remission assessment of rheumatoid arthritis in daily practice in China: a cross-sectional observational study. ACR/EULAR, bDMARDs, CDAI, DMARD, LEF, MTX, RA, SSZ
60  2018 Structural damage progression in patients with early rheumatoid arthritis treated with methotrexate, baricitinib, or baricitinib plus methotrexate based on clinical response in the phase 3 RA-BEGIN study. CDAI, JAK, MTX
61  2018 The relationship between bristol rheumatoid arthritis fatigue scales and disease activity of patients with rheumatoid arthritis. BRAF-MDQ, BRAF-NRS, CDAI, RA
62  2018 [S2e guideline: treatment of rheumatoid arthritis with disease-modifying drugs]. ---
63  2017 Achieving simplified disease activity index remission in patients with active rheumatoid arthritis is associated with subsequent good functional and structural outcomes in a real-world clinical setting under a treat-to-target strategy. CDAI, HAQ-DI, LDA, RA
64  2017 Adherence to combination DMARD therapy and treatment outcomes in rheumatoid arthritis: a longitudinal study of new and existing DMARD users. DAS28, mHAQ, RA
65  2017 Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. DMARD, SAEs
66  2017 Brief Report: Remission Rates With Tofacitinib Treatment in Rheumatoid Arthritis: A Comparison of Various Remission Criteria. CDAI, DAS28, RA
67  2017 Circulating cell free DNA: a marker to predict the therapeutic response for biological DMARDs in rheumatoid arthritis. ccfDNA, DMARDs, EULAR, OA, RA
68  2017 Clinical Characteristics of Rheumatoid Arthritis Patients Achieving Functional Remission after Six Months of Non-tumor Necrosis Factor Biological Disease-Modifying Antirheumatic Drugs (DMARDs) Treatment. ADL, DMARDs, HAQ, MCS, PCS, PGA, PTGA, QOL, RA, RCS, SF, TJC, TNF
69  2017 Clinical Characteristics of Rheumatoid Arthritis Patients Achieving Functional Remission with Six Months of Biological DMARDs Treatment. bDMARDs, HAM-D, HAQ-DI, RA, SDS, SF
70  2017 Comparative Assessment of the Different American College of Rheumatology/European League Against Rheumatism Remission Definitions for Rheumatoid Arthritis for Their Use as Clinical Trial End Points. ACR, CDAI, EULAR, MTX, RA
71  2017 Comparison between different disease activity scores in rheumatoid arthritis: an Egyptian multicenter study. ACR, CDAI, DAS, DAS28-ESR, EULAR, MHAQ, RA
72  2017 Comparison of physical function in early rheumatoid arthritis patients treated with biologics for 1year who achieved clinical remission or low disease activity. RA
73  2017 Continual Maintenance of Remission Defined by the ACR/EULAR Criteria in Daily Practice Leads to Better Functional Outcomes in Patients with Rheumatoid Arthritis. ACR, CDAI, EULAR, J-HAQ, RA
74  2017 Correlation between rapid-3, DAS28, CDAI and SDAI as a measure of disease activity in a cohort of Colombian patients with rheumatoid arthritis. CDAI, DAS28, MDHAQ, RA, RAPID3, VAS
75  2017 Determining the acceptable level of physician compliance with a treat-to-target strategy in early rheumatoid arthritis. CDAI, DAS28, LDA, ROC
76  2017 Disease activity is associated with reduced left ventricular systolic myocardial function in patients with rheumatoid arthritis. GLS, LV, RA, scMWS
77  2017 Drug interaction between methotrexate and salazosulfapyridine in Japanese patients with rheumatoid arthritis. MMP-3, MTX, RA, SASP
78  2017 Global assessments of disease activity are age-dependent determinant factors of clinical remission in rheumatoid arthritis. RA
79  2017 Long noncoding RNA profiling revealed differentially expressed lncRNAs associated with disease activity in PBMCs from patients with rheumatoid arthritis. lncRNAs, PBMCs, RA
80  2017 Mizoribine Synchronized Methotrexate Therapy should be Considered when Treating Rheumatoid Arthritis Patients with an Inadequate Response to Various Combination Therapies. DAS28, DMARDs, MTX, MZR, RA
81  2017 Need for Improvement in Current Treatment of Psoriatic Arthritis: Study of an Outpatient Clinic Population. CASPAR, CPDAI, DAPSA, DAS28, DLQI, ESR, MDA, PASDAS, PASI, PsA
82  2017 Predictor of the Simplified Disease Activity Index 50 (SDAI 50) at Month 3 of bDMARD Treatment in Patients with Long-Established Rheumatoid Arthritis. bDMARDs, ESR, EULAR, RA, SDAI50
83  2017 Remission induction by Raising the dose of Remicade in RA (RRRR) study: Rationale and study protocol for a randomized controlled trial comparing for sustained clinical remission after discontinuation of infliximab in patients with rheumatoid arthritis. ---
84  2017 Routine Assessment of Patient Index Data 3 and the American College of Rheumatology/European League Against Rheumatism Provisional Remission Definitions as Predictors of Radiographic Outcome in a Rheumatoid Arthritis Clinical Trial With Tocilizumab. DI, HAQ, RA, RAPID3, SJC, VAS
85  2017 Simplified Disease Activity Index remission at month 6 is an independent predictor of functional and structural remissions at month 12 during abatacept treatment in patients with rheumatoid arthritis: A multi-center, prospective cohort study in Japan. mTSS, OR, RA
86  2017 The influence of fibromyalgia on achieving remission in patients with long-standing rheumatoid arthritis. bDMARDs, csDMARDs, FM, mRDCI, PDQ, RA, VAS
87  2017 The Relationship between the Serum Oxytocin Levels, Disease Activity, the ADLs and the QOL in Patients with Rheumatoid Arthritis. ADLs, bDMARDs, HAM-D, OXT, QOL, RA, SF
88  2017 Vitamin D and Calcium Are Required during Denosumab Treatment in Osteoporosis with Rheumatoid Arthritis. BAP, BMD, DAS28-CRP, HAQ-DI, MMP-3, OP, P1NP, RA, TRACP
89  2016 A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study. ACR, CDAI, DAS28, EULAR, MTX, PD, PK, RA, RP
90  2016 Achievement of Remission and Low Disease Activity Definitions in Patients with Rheumatoid Arthritis in Clinical Practice: Results from the NOR-DMARD Study. ACR, CDAI, DMARD, EULAR, LDA, RA
91  2016 ACR/EULAR Definitions of Remission Are Associated with Lower Residual Inflammatory Activity Compared with DAS28 Remission on Hand MRI in Rheumatoid Arthritis. ACR/EULAR, BME, DAS28, h-MRI, RA
92  2016 Active Foot Synovitis in Patients With Rheumatoid Arthritis: Unstable Remission Status, Radiographic Progression, and Worse Functional Outcomes in Patients With Foot Synovitis in Apparent Remission. CDAI, RA, SF-36
93  2016 Baricitinib in Patients with Refractory Rheumatoid Arthritis. ACR20, DMARDs, HAQ-DI
94  2016 Brief Report: Estimating Disease Activity Using Multi-Biomarker Disease Activity Scores in Rheumatoid Arthritis Patients Treated With Abatacept or Adalimumab. CDAI, MBDA, RA, RAPID3
95  2016 Changes in Ultrasonographic Vascularity Upon Initiation of Adalimumab Combination Therapy in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate. ADA, CDAI, MCP2, MTX, PDUS, RA, SJC66, TJC68, US
96  2016 Comparison of the efficacies of abatacept and tocilizumab in patients with rheumatoid arthritis by propensity score matching. RF
97  2016 Effect of Adherence to Protocolized Targeted Intensifications of Disease-modifying Antirheumatic Drugs on Treatment Outcomes in Rheumatoid Arthritis: Results from an Australian Early Arthritis Cohort. DAS28, RA
98  2016 Effectiveness of abatacept for patients with Sjogren's syndrome associated with rheumatoid arthritis. An open label, multicenter, one-year, prospective study: ROSE (Rheumatoid Arthritis with Orencia Trial toward Sjogren's syndrome Endocrinopathy) trial. RA, SS
99  2016 Effects of Achieving Target Measures in Rheumatoid Arthritis on Functional Status, Quality of Life, and Resource Utilization: Analysis of Clinical Practice Data. CDAI, DAS28-CRP, DME, EQ-5D, LDA, MDA, mHAQ, SDA
100  2016 Efficacy and safety of golimumab in Indian patients with rheumatoid arthritis: Subgroup data from GO-MORE study. EULAR, RA